These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27605066)

  • 1. Autoimmune meningoencephalitis in a melanoma patient treated with ipilimumab.
    Choe JH; Andonian BJ; Kim GJ; Salama AK
    Immunotherapy; 2016 Oct; 8(10):1163-7. PubMed ID: 27605066
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute autoimmune myocarditis and hepatitis due to ipilimumab monotherapy for malignant melanoma.
    Samara Y; Yu CL; Dasanu CA
    J Oncol Pharm Pract; 2019 Jun; 25(4):966-968. PubMed ID: 29444608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases.
    Garcia CA; El-Ali A; Rath TJ; Contis LC; Gorantla V; Drappatz J; Davar D
    J Immunother Cancer; 2018 Aug; 6(1):83. PubMed ID: 30170622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature.
    Abdallah AO; Herlopian A; Ravilla R; Bansal M; Chandra-Reddy S; Mahmoud F; Ong S; Gokden M; Hutchins L
    J Oncol Pharm Pract; 2016 Jun; 22(3):537-42. PubMed ID: 25712627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute visual loss after ipilimumab treatment for metastatic melanoma.
    Wilson MA; Guld K; Galetta S; Walsh RD; Kharlip J; Tamhankar M; McGettigan S; Schuchter LM; Fecher LA
    J Immunother Cancer; 2016; 4():66. PubMed ID: 27777775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Acutely induced diabetes mellitus in a 63-year-old female after treatment with ipilimumab for metastatic melanoma].
    Jørgensen LB; Yderstræde K
    Ugeskr Laeger; 2017 Sep; 179(37):. PubMed ID: 28918779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma.
    Hwang SJ; Carlos G; Wakade D; Sharma R; Fernandez-Penas P
    Melanoma Res; 2016 Aug; 26(4):417-20. PubMed ID: 27031538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy.
    Eryılmaz MK; Mutlu H; Salim DK; Musri FY; Tural D; Başsorgun I; Coşkun HŞ
    J Oncol Pharm Pract; 2016 Jun; 22(3):533-6. PubMed ID: 25694346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma.
    Tsiogka A; Jansky GL; Bauer JW; Koelblinger P
    Melanoma Res; 2017 Oct; 27(5):524-525. PubMed ID: 28858175
    [No Abstract]   [Full Text] [Related]  

  • 10. A Life-Threatening Cause of Colitis.
    Jaswani TS; Grider DJ; Bern MJ
    Gastroenterology; 2018 Jan; 154(1):35-36. PubMed ID: 28918915
    [No Abstract]   [Full Text] [Related]  

  • 11. Survival After Fulminant Myocarditis Induced by Immune-Checkpoint Inhibitors.
    Arangalage D; Delyon J; Lermuzeaux M; Ekpe K; Ederhy S; Pages C; Lebbé C
    Ann Intern Med; 2017 Nov; 167(9):683-684. PubMed ID: 28869988
    [No Abstract]   [Full Text] [Related]  

  • 12. Sweet syndrome associated with ipilimumab in a patient with metastatic melanoma.
    Adler NR; Murray WK; Brady B; McCormack C; Pan Y
    Clin Exp Dermatol; 2018 Jun; 43(4):497-499. PubMed ID: 29396853
    [No Abstract]   [Full Text] [Related]  

  • 13. A case of aseptic meningitis without neck rigidity occurring in a metastatic melanoma patient treated with ipilimumab.
    Oishi K; Nakao M; Maeda S; Matsushita T; Ikeda T; Yamada T; Takehara K; Hamaguchi Y
    Eur J Dermatol; 2017 Apr; 27(2):193-194. PubMed ID: 28007669
    [No Abstract]   [Full Text] [Related]  

  • 14. Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases.
    Pushkarevskaya A; Neuberger U; Dimitrakopoulou-Strauss A; Enk A; Hassel JC
    J Immunother; 2017 Sep; 40(7):282-285. PubMed ID: 28604554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypophysitis and other autoimmune complications related to immune checkpoints inhibitors´ treatment: Spectrum of imaging appearances.
    Malikova H; Holesta M; Fialova A; Arenbergerova M; Weichet J
    Neuro Endocrinol Lett; 2018 Sep; 39(3):196-204. PubMed ID: 30431741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Mayo Clinic Experience With the Neurological Complications of the CTLA-4 Inhibitor Ipilimumab.
    Ruff MW; Mauermann ML
    Neurologist; 2018 May; 23(3):98-99. PubMed ID: 29722744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ipilimumab-associated halo-like inflammatory reactions around nevi during therapy for metastatic melanoma.
    Alniemi DT; Fischer A; Greene LA; Pierson JC
    Dermatol Online J; 2018 Jul; 24(7):. PubMed ID: 30261564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition.
    van den Brom RR; Abdulahad WH; Rutgers A; Kroesen BJ; Roozendaal C; de Groot DJ; Schröder CP; Hospers GA; Brouwer E
    Rheumatology (Oxford); 2016 Jun; 55(6):1143-5. PubMed ID: 27069016
    [No Abstract]   [Full Text] [Related]  

  • 19. Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab.
    Omodaka T; Kiniwa Y; Sato Y; Suwa M; Sato M; Yamaguchi T; Sato A; Miyake T; Okuyama R
    J Dermatol; 2018 Oct; 45(10):e289-e290. PubMed ID: 29667767
    [No Abstract]   [Full Text] [Related]  

  • 20. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
    Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
    Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.